| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eiger BioPharmaceuticals, Inc. | CEO, Director | Stock Option (Right to Buy) | 750,000 | 03 Jul 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000114036123033483-apelian-david-2023-07-03 | Eiger BioPharmaceuticals, Inc. | 03 Jul 2023 | 1 | $0 | 4 | CEO, Director | 06 Jul 2023, 17:37 |
| /report/000156761923001760-apelian-david-2023-01-31 | Eiger BioPharmaceuticals, Inc. | 31 Jan 2023 | 1 | $0 | 4 | Interim CEO, Director | 02 Feb 2023, 20:12 |
| /report/000156761922016461-apelian-david-2022-08-16 | Eiger BioPharmaceuticals, Inc. | 16 Aug 2022 | 1 | -$49,030 | 4 | Director | 18 Aug 2022, 17:36 |
| /report/000114036122009254-apelian-david-2022-03-11 | Eiger BioPharmaceuticals, Inc. | 11 Mar 2022 | 2 | $0 | 4 | Director | 11 Mar 2022, 20:06 |